top of page

Acievements

2021年

2021

Original paper

  1. Evaluation of hepatic CYP3A4 enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasoneand aprepitant.  Hibino H, Sakiyama N, Makino Y, Makihara-Ando R, Horinouchi H, Fujiwara Y, Kanda S, Goto Y, Yoshida T, Okuma Y, Shinno Y, Murakami S, Hashimoto H, Akiyoshi T, Imaoka A, Ohe Y, Yamaguchi M, Ohtani H.  EurJClin Pharmacol . (2022)

  2. Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol.  Akiyoshi T, Uchiyama M, Inada R, Imaoka A, Ohtani H.  Drug Metab Pharmacokinet .  

  3. Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants.  Akiyoshi T, Naitou R, Imaoka A, Miyazaki M, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H.  Int J Pharmacol Ther .

  4. Digoxin absorption decreased independency of P-gp activity in rats with irinotecan-induced gastrointestinal damage.  Tsuchitani T, Akiyoshi T, Imaoka A, Ohtani H.  J Pharm Health Care Sci .7 (1): 24.

  5. Estimation of absolute oral bioavailability without performing an intravenous clinical study . Ohtani H, Iwata R, Imaoka A, Akiyoshi T.  Drug Metab Pharmacokinet .

  6. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Yamaguchi Y, Akiyoshi T, Kawamura G, Imaoka A, Miyazaki M, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H.  Drug Metab Pharmacokinet .

  7. Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report.  Hibino H, Makino Y, Sakiyama N, Makihara-Ando R, Hashimoto H, Akiyoshi T, Imaoka A, Fujiwara Y, Ohe Y, Yamaguchi M, Ohtani H.  Int J Pharmacol Ther . 59 (4): 328-332.

Review article

  1. Unique perspectives of pharmacy education in Japan -Core curriculum and some examples of advanced education.  Ohtani H.  J Asian Assoc Sch Pharm .

​国際学会招待講演

  1. Hisakazu Ohtani. Unique perspectives of pharmacy education in Japan -core curriculum and advanced education-. 6th AASP Pharmacy Education Forum 2021, Web (2021.7)

国内学会招待講演

  1. 大谷 壽一. 薬物動態の基礎から臨床応用までを読み解き、質の高い患者指導に活かす. 健工総合研究所「食品･グレープフルーツと医薬品との相互作用」アップデート, Web (2021.5)

  2. 大谷 壽一. 医看薬系のキャリアパスを考える. 第 16 回慶應赤倉アカデミー, Web (2021.10)

  3. 大谷 壽一. 医薬品情報を科学的に読み解く～薬物動態と薬物相互作用を中心に～. 第 30 回 高崎健康福祉大学薬学部生涯研修セミナー, Web (2021.11)

  4. 大谷 壽一. 医療法改正に伴う病院薬剤師としての働き方. 慶應関連薬剤部長会 第 41 回 学術講演会, Web (2022.1)

  5. 大谷 壽一. 医薬品情報から薬物相互作用を読み取る. 東京都薬剤師会 令和 3 年度 薬局業務研修会, Web (2022.2)

Conference presentation

  1. Quantitative estimation of the permeability of P-gp pertaining across cell monolayer from the ATPase activity and absolute abundance of P-gp.  Tsuchitani T, Akiyoshi A, Imaoka A, Ohtani H. 24th North American ISSX Meeting, Web, 2021.9

  2. Time-dependent inhibitory properties of natural fruit components against CYP2C19 genetic variants.  Hiroyuki Seki, Takeshi Akiyoshi, Miyuki Shimo, Ayuko Imaoka, Hiroshi Yamazaki, Katsunori Nakamura, Toshikazu Otani. Medical Pharmacy Forum 2021, Web, 2021.7

  3. Evaluation of fexofenadine transport characteristics by wild-type and mutant OATP1A2.  Hiroshi Han, Tokio Morita, Takeshi Akiyoshi, Hiroki Kataoka, Ayuko Imaoka, Kazuhiro Katayama, Toshikazu Otani. Medical Pharmacy Forum 2021, Web, 2021.7

  4. Evaluation of transport properties of mutant OATP1A2 / OATP2B1 using quantitative targeted proteomics.  Hiroki Kataoka, Takeshi Akiyoshi, Tokio Morita, Hirohiro Yajima, Ayuko Imaoka, Kazuhiro Katayama, Yasuo Uchida, Tetsuya Terasaki, Toshikazu Otani. Medical Pharmacy Forum 2021, Web, 2021.7

  5. * 23 Effect of mutant allele on metabolic kinetics of CYP2C19 and factors of its substrate difference.  Daitomo Watanabe, Yusaku Kurita, Takeshi Akiyoshi, Hiroyuki Seki, Ayuko Imaoka, Norie Murayama, Hiroshi Yamazaki, Miyuki Shimo, Katsunori Nakamura, Toshikazu Otani. Medical Pharmacy Forum 2021, Web, 2021.7

  6. Effect of pH on the enzymatic activity of CYP2C19 variants.  Risa Ikeda, Takeshi Akiyoshi, Hiroyuki Seki, Ayuko Imaoka, Hiroshi Yamazaki, Miyuki Shimo, Katsunori Nakamura, Toshikazu Otani. Medical Pharmacy Forum 2021, Web, 2021.7

  7. Do Mutations in Metabolizing Enzymes Cause Individual Differences in Drug Interactions? ~ In silico approach.  Yusuke Sakai, Noe Miyazaki, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. The 23rd Annual Meeting of the Japanese Society of Pharmaceutical Informatics, Web, 2021.6

  8. Examination of gastrointestinal OATPs inhibitory activity by cranberry juice and search for its inhibitory component.  Tokio Morita, Satoshi Tsuchiya, Takeshi Akiyoshi, Hirohiro Yajima, Kazuhiro Katayama, Ayuko Imaoka, Toshikazu Otani. Winner of the 4th Freshers Conference, Web, 2021.6 Excellent Presentation Award

  9. Effect of pH on the metabolic activity of CYP2C9 various genetic variants.  Kenji Kanagawa, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. Received the 4th Freshers Conference, Web, 2021.6 Excellent Presentation Award .

  10. The effect of ultrafine bubbles on the stability of supersaturated solutions of poorly soluble drugs.  Sayuri Kimura, Ayuko Imaoka, Takeshi Akiyoshi, Toshiya Tanaka, Satoko Fujioka, Koichi Terasaka, Toshikazu Otani. Winner of the 4th Freshers Conference, Web, 2021.6 Excellent Presentation Award

  11. Inhibitory properties of the fruit component naringenin and its glycosides against the OAPT1A2 mutant.  Naoya Araki, Tokio Morita, Takeshi Akiyoshi, Hiroki Kataoka, Kazuhiro Katayama, Ayuko Imaoka, Toshikazu Otani. 4th Freshers Conference, Web, 2021.6

国内学会発表

  1. 森田 時生, 土谷 聡耀, 秋好 健志, 矢島 広大, 片山 和浩, 今岡 鮎子, 大谷 壽一. クランベリージュースによる消化管 OATPs 阻害活性の検討とその阻害成分の探索. 第 4 回フレッシャーズカンファランス, Web, 2021.6　優秀発表賞受賞

  2. 金川 謙治, 秋好 健志, 今岡 鮎子, 大谷 壽一. CYP2C9 各種遺伝的 variants の代謝活性に対する pH の影響. 第 4 回フレッシャーズカンファランス, Web, 2021.6　優秀発表賞受賞

  3. 木村 早百合, 今岡 鮎子, 秋好 健志, 田中 俊也, 藤岡 沙都子, 寺坂 宏一, 大谷 壽一. 難溶性薬物の過飽和溶液の安定性に対するウルトラファインバブルの影響. 第 4 回フレッシャーズカンファランス, Web, 2021.6　優秀発表賞受賞

  4. 荒木 尚哉, 森田 時生, 秋好 健志, 片岡 寛樹, 片山 和浩, 今岡 鮎子, 大谷 壽一. OAPT1A2 変異型に対する果実成分ナリンゲニン及びその配糖体の阻害特性. 第 4 回フレッシャーズカンファランス, Web, 2021.6

  5. 酒井 悠輔, 宮﨑 乃絵, 今岡 鮎子, 秋好 健志, 大谷 壽一. 代謝酵素の変異は薬物相互作用に個人差をもたらすか？～in silico でのアプローチ. 第 23 回日本医薬品情報学会・総会, Web, 2021.6

  6. 関 博行, 秋好 健志, 下地 みゆき, 今岡 鮎子, 山崎 浩史, 中村 克徳, 大谷 壽一. CYP2C19 遺伝的 variants に対する天然果実成分の時間依存的阻害特性. 医療薬学フォーラム 2021, Web, 2021.7

  7. 韓 弘燁, 森田 時生, 秋好 健志, 片岡 寛樹, 今岡 鮎子, 片山 和浩, 大谷 壽一. 野性型及び変異型 OATP1A2 によるフェキソフェナジンの輸送特性評価. 医療薬学フォーラム 2021, Web, 2021.7

  8. 片岡 寛樹, 秋好 健志, 森田 時生, 矢島 広大, 今岡 鮎子, 片山 和浩, 内田 康雄, 寺崎 哲也, 大谷 壽一. 定量的標的プロテオミクスを用いた変異型 OATP1A2/OATP2B1 の輸送特性の評価. 医療薬学フォーラム 2021, Web, 2021.7

  9. 渡辺 大智, 栗田 祐作, 秋好 健志, 関 博行, 今岡 鮎子, 村山 典恵, 山崎 浩史, 下地 みゆき, 中村 克徳, 大谷 壽一. CYP2C19 の代謝キネティクスにおける *23 変異アレルの影響と、その基質間差の要因. 医療薬学フォーラム 2021, Web, 2021.7

  10. 池田 理紗, 秋好 健志, 関 博行, 今岡 鮎子, 山崎 浩史, 下地 みゆき, 中村 克徳, 大谷 壽一. CYP2C19 variants の酵素活性に及ぼす pH の影響. 医療薬学フォーラム 2021, Web, 2021.7

  11. 大島 幸徳, 岡部 健大, 沖横田 麻菜, 大森 美緒, 大口 顕, 亀ヶ谷 健, 宮本 勵, 岡崎 光洋, 大谷 壽一. 患者の食習慣や嗜好に係る服薬指導の現状と薬剤師の行動や意識 -「医薬品とグレープフルーツの相互作用」調査から見えたもの-. 第 15 回日本薬局学会学術総会, 福岡/Web (ハイブリッド), 2021.11

  12. 土谷 聡耀, 秋好 健志, 今岡 鮎子, 大谷 壽一. 消化管吸収過程における P 糖蛋白質を介した薬物相互作用の in vitro ATPase 活性からの予測. 日本薬学会第 142 年会, Web, 2022.3

  13. 片岡 寛樹, 冬木 陽大, 秋好 健志, 森田 時生, 矢島 広大, 今岡 鮎子, 片山 和浩, 大谷 壽一. OATP1A2 variants の輸送活性に対する温度の影響. 日本薬学会第 142 年会, Web, 2022.3

  14. 鈴木 玲奈, 今岡 鮎子, 秋好 健志, 大谷 壽一. マグネシウムの消化管吸収に対するシプロフロキサシンの影響. 日本薬学会第 142 年会, Web, 2022.3

著書

  1. 大谷 壽一 (著)、カネダ工房 (イラスト)、ビーコムプラス (編)「マンガでわかる薬物動態学」、オーム社 (2021/5)

  2. 堀岡 正義 (原著)、調剤学総論編集委員会 (折井 孝男、二神 幸次郎、山本 信夫、大谷 壽一) (著)、「調剤学総論」改訂 14 版、南山堂、2022 年 2 月

2020年

2020

Original paper

  1. Relative contributions of metabolic enzymes to systemic elimination can be estimated from clinical DDI studies: Validation using an in silico approach.  Koinuma K, Tsuchitani T, Imaoka A, Akiyoshi T, Ohtani H.  Int J Pharmacol Ther . 59 (3): 231-238.

  2. Citrus fruit-derived flavanone glycoside narirutin is a novel potent inhibitor of organic anion-transporting polypeptides.  Tsuchitani T, Akiyoshi T, Imaoka A, Ohtani H.  J Agric Food Chem. 68 (48): 14182-14191.

  3. Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro .  Semba Y, Akiyoshi T, Hibino H, Imaoka A, Ohtani H.  Int J Pharmacol Ther. 58 (10): 539-542.

  4. Novel method to estimate the appropriate dosing interval for activated charcoal to avoid interaction with other drugs. Ohtani H, Nakamura K, Imaoka A, Akiyoshi T.  Eur J Clin Pharmacol. 76 (11): 1529-1537.

  5. pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2.  Morita T, Akiyoshi T, Sato R, Katayama K, Yajima K, Kataoka H, Imaoka A, Sugimoto Y, Ohtani H.  Drug Metab Pharmacokinet. 35 (2): 220-227.

Invited lecture at the conference

  1. Endless struggle with English presentations and English dissertations-Steps to overcome weaknesses-. 30th Annual Meeting of the Japanese Society of Pharmaceutical Health Care, Symposium 5 "Development of Next-Generation Leaders to Solve Clinical Issues in Cancer Chemotherapy", Symposist, Web, 2020.9

Conference presentation

  1. Preparation and evaluation of a cross-grade rubric evaluation table for measuring the achievement of ethics and communication ability development in the Faculty of Pharmacy.  Kae Inoue, Satoko Ishikawa, Daiki Ichikawa, Ayuko Imaoka, Hiroki Iwata, Hitoshi Kawazoe, Masaki Kimura, Noriko Kobayashi, Tomonori Nakamura, Eriko Yokota, Naomi Urushihara.

2019年

2019

Original paper

  1. Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate. Hattori T, Imaoka A, Akiyoshi T, Ohtani H. Biopharm Drug Dispos. 40 (9): 315-324.

  2. Effects of food type on the extent of drug-drug interactions between activated charcoal and phenobarbital in rats. Ogata Y, Imaoka A, Akiyoshi T, Ohtani H. Drug Metab Pharmacokinet. 34 (4): 287-291.

  3. Inhibitory kinetics of fruit components on CYP2C19 activity. Seki H, Akiyoshi T, Imaoka A, Ohtani H. Drug Metab Pharmacokinet. 34 (3): 181-186.

  4. The extent of drug-drug interaction between amlodipine and activated charcoal is attenuated by food intake in rats. Imaoka A, Seki K, Akiyoshi T, Ohtani H. Drug Metab Pharmacokinet. 34 (1): 108-110.

  5. Unauthorized and unlicensed drug listings at internet auctions. Toshikazu Otani, Moemi Fujii, Ayuko Imaoka, Takeshi Akiyoshi. Medical Pharmacy. 45 (10): 591-595.

Invited lecture at the conference

  1. Know-how for submitting papers-Points for manuscript preparation and revise-. Toshikazu Otani. 29th Annual Meeting of the Japanese Society of Pharmaceutical Health Care, Symposium 18 "Leading Leading Research Leaders Should Have to Solve Clinical Issues in Cancer Chemotherapy" Viewpoint ”, Symposist, Fukuoka, 2019.11

  2. How to read and use drug information on pharmacokinetics and drug interactions . Toshikazu Otani. Reiwa 2nd Year 1st Tokorozawa City Pharmacist Association Academic Lecture, Tokorozawa, 2020.1

Conference presentation

  1. Comparative analysis of human cytochrome P450 2C19 enzyme kinetics among six variants. Daichi Watanabe, Miyuki Shimoji, Hiroyuki Seki, Takeshi Akiyoshi, Ayuko Imaoka, Akikazu Murakami, Hidehiro Kishimoto, Norie Murayama, Hiroshi Yamazaki, Katsunori Nakamura, Hisakazu Ohtani. 9th AASP Conference, Suwon, 2019.7

  2. Comparison of resveratrol and sesamin inhibitory properties in CYP2C9 genetic variants. Rino Inada, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. The 140th Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, 2020.3

  3. Effect of temperature on metabolic activity of CYP2C19 mutant molecular species. Sumie Zhao, Takeshi Akiyoshi, Daitomo Watanabe, Hiroyuki Seki, Ayuko Imaoka, Hiroshi Yamazaki, Miyuki Shimo, Katsunori Nakamura, Toshikazu Otani. Kyoto, 2020.3

  4. High and low affinity kinetics of OATP2B1 --Inhibitory potency and pH-dependency of inhibitors-. Ryo Sato, Takeshi Akiyoshi, Ayuko Imaoka, Kazuhiro Katayama, Yoshikazu Sugimoto, Hisakazu Ohtani.

  5. Search for novel OATP2B1 inhibitory components in citrus juice and quantitative evaluation of their inhibitory activity. Tokio Morita, Takeshi Akiyoshi, Hirohiro Yajima, Ayuko Imaoka, Yoshinori Uekusa, Fumiyuki Kiuchi, Kazuhiro Katayama, Yoshikazu Sugimoto, Toshikazu Otani. The 13th Symposium on Young Medical and Pharmaceutical Sciences for the Next Generation, Gifu, 2019.10

  6. Effect of pH on metabolic activity of various genetic variants of CYP3A4 Rina Ejiri, Takeshi Akiyoshi, Ayuko Imaoka, Guengerich FP, Katsunori Nakamura, Kojiro Yamamoto, Toshikazu Otani. Medical Pharmacy Forum 2019, Hiroshima, 2019.7

  7. Evaluation of validity of calculation of metabolic pathway contribution rate based on drug interaction clinical trials. Kana Hinuma, Satoshi Tsuchiya, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. 3rd Freshers Conference, Tokyo, 2019.6

  8. Verification of estimation accuracy of absolute bioavailability estimation method without using intravenous data. Natsumi Iwata, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. 22nd Annual Meeting of the Japan Society for Pharmaceutical Informatics, Sapporo, 2019.6

2018年

2018

Original paper

  1. Food intake emitters the drug interaction between new quinolones and aluminum. Imaoka A, Abiru K, Akiyoshi T, Ohtani H. J Pharm Health Care Sci. 4 (11). 

  2. 5-fluorouracil-induced gastrointestinal damage impairs the absorption and anticoagulant effects of dabigatran etexilate. Tsujii K, Hattori T, Imaoka A, Akiyoshi T, Ohtani H. J Pharm Sci. 107 (5): 1430-1433.

Invited lecture at the conference

  1. Pharmacokinetics and Personalized Medicine Topics. Toshikazu Otani. Ministry of Defense Pharmacy Roundtable, Tokyo, July 2018 

  2. Understanding and mastering information on drug interactions . Toshikazu Otani. Ota Ward Pharmacist Association District Workshop, Tokyo, August 2018

  3. Iroha of writing a dissertation that is difficult to hear. Toshikazu Otani. 28th Annual Meeting of the Japanese Society of Pharmaceutical Health Care, Symposium 29 "How to Start and Practice Clinical Research-Aiming for Dissertation-", Symposist, Kobe, 2018.11

  4. Overseas clinical rotation and exchange program of pharmacy students in Keio University. Takeshi Akiyoshi. 28th Annual Meeting of the Japanese Society of Medical Pharmacy, International Symposium "Pharmacy Education, Research and Practice Models in Asia", Symposist, Kobe, 2018.11

Conference presentation

  1. In silico evaluation of clinical effects caused by differences in inhibitor sensitivity between CYP2D6 variants. Noe Miyazaki, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. 62nd Annual Meeting of the Pharmaceutical Society of Japan, Kanto Branch, Tokyo, September 2018

  2. Analysis of pH sensitive transport characteristics of human small intestine organic anion transport polypeptides OATP1A2 and OATP2B1. Tokio Morita, Ryo Sato, Takeshi Akiyoshi, Ayuko Imaoka, Kazuhiro Katayama, Yoshikazu Sugimoto, Toshikazu Otani. Branch Meeting, Tokyo, September 2018

  3. PH dependence of the transport capacity of human small intestine organic anion transport polypeptides OATP1A2 and 2B1. Tokio Morita, Ryo Sato, Takeshi Akiyoshi, Ayuko Imaoka, Kazuhiro Katayama, Yoshikazu Sugimoto, Toshikazu Otani. 2nd Freshers Conference, Kyoto , 2018.7

  4. Effect of diet and its viscosity on the degree of interaction between phenobarbital and activated carbon. Takayoshi Yoshiike, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. Medical Pharmacy Forum 2018, Tokyo, 2018.6

2017年

2017

Original paper

  1. 5-Fluorouracil treatment alters the expression of intestinal transporters in rats. Yotsumoto K, Akiyoshi T, Wada N, Imaoka A, Ohtani H. Biopharm Drug Dispos . 38 (9): 509-516 (2017)

  2. Development and evaluation of an overseas clinical rotation program for undergraduate pharmacy students in Japan. Ohtani H, Mitsui R, AkiyoshiT, ImaokaA, Abe Y, Kanke M, Nakamura T, Foster P, Mochizuki M. Curr Pharm Teach Learn . 9 (3) : 452-459 (2017)

  3. Analysis of the mechanism of prolonged persistence of drug interaction between terbinafine and amitriptyline or nortriptyline . Mikami A, Hori S, Ohtani H, Sawada Y. Biol. Pharm. Bull . 40: 1010-1020 (2017)

  4. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin. Ishikawa Y, Akiyoshi T, Imaoka A, Ohtani H. Biopharm Drug Dispos . 38 (7): 420-425 (2017)

  5. Implementation and evaluation of new advanced medication instruction pre-training based on student needs. Saya Suzuki, Izumi Aono, Natsumi Imai, Aki Kuwahara, Yuki Muta, Minako Matsumoto, Aya Yoshida, Asuka Watanabe, Akira Takagi , Noriko Kobayashi, Haruko Saeki, Toshikazu Otani, Tomonori Nakamura, Junko Kizu. Yakugaku Zasshi . 137 (11): 1391-1408 (2017)

Invited lecture at the conference

  1. Pharmacy  education  in  Japan -Clinical  rotation  and  preceptorship -seminar national. Ohtani  H. Asosiasi  Pendidikan Tinggi Farmasi Indonesia (APTFI) II, Banjarmasin, Indonesia, 2017.11

  2. Accepted and not accepted papers. Toshikazu Otani. 1st Japanese Society of Pharmaceutical Health Care Seminar, Tokyo, 2017.4

  3. How to connect the learning of languages and specialized subjects to English communication skills?  Toshikazu Otani. 61st Annual Meeting of the Pharmaceutical Society of Japan, Kanto Branch, Symposium 5 "Toward the Internationalization of Pharmacists and Clinical Pharmacy", Organizers and Symposists, Tokyo, September 2017

  4. Information literacy education model proposal for medical (pharmacy field).  Toshikazu Otani.  (Video announcement),  (Public corporation) Private University Information Education Association 2017 Education Reform ICT Strategy Conference Subcommittee D: Information literacy education model for problem finding and solution thinking aimed at creating value, Tokyo, September 2017

  5. The basics of clinical pharmacokinetics required of pharmacists in collaboration with pharmaceuticals.  Toshikazu Otani. Training Lecture for Pharmacists, Kanto Branch, Pharmaceutical Society of Japan "What is required for medical cooperation-from basics to practice-", Maebashi, 2017.10

  6. How to read and use drug interaction information. Toshikazu Otani. 158th Pharmaceutical Society of Japan, Niigata, 2018.2

​Conference presentation

  1. Differences in temperature sensitivity among CYP3A4 genetic variants. Takeshi Akiyoshi, Kanami Machida, Ayuko Imaoka, FP Guengerich, Katsunori Nakamura, Kojiro Yamamoto, Toshikazu Otani.

  2. Evaluation of CYP2C19 metabolic activity inhibition mode and kinetics of natural fruit components. Hiroyuki Seki, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. Pharmaceutical Society of Japan 138th Annual Meeting, Kanazawa, 2018.3

  3. Construction of absolute oral bioavailability estimation method for drugs without intravenous data. Risa Iwata, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. 61st Annual Meeting of the Pharmaceutical Society of Japan, Kanto Branch, Tokyo, September 2017

  4. Effect of gastrointestinal disorders caused by irinotecan on absorption of digoxin. Satoshi Tsuchiya, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. 61st Annual Meeting of the Japanese Pharmacy Society Kanto Branch, Tokyo, September 2017 Received the Excellent Presentation Award

  5. Information literacy education model for problem discovery / solution thinking aimed at creating value. Toshikazu Otani. 2017 Education Reform ICT Strategy Conference, Subcommittee D, Tokyo, September 2017 (Preliminary shooting video announcement)

  6. Construction and evaluation of administration design method for avoiding interaction between pharmaceuticals and activated carbon. Yukio Nakamura, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. 20th Annual Meeting of the Japan Society for Pharmaceutical Informatics, Tokyo, July 2017 Received the Excellent Presentation Award

  7. Consumer Awareness Survey on the Illegal Resale / Transfer of Pharmaceuticals to Third Parties. Moemi Fujii, Ayuko Imaoka, Takeshi Akiyoshi, Mayumi Mochizuki, Katsunori Yamaura, Toshikazu Otani. 20th Annual Meeting of the Japanese Society of Pharmaceutical Informatics / Academic Conference, Tokyo, July 2017

  8. Effects of gastric pH and diet on drug absorption-evaluation using small animals-. Ayuko Imaoka, Kohei Seki, Takeshi Akiyoshi, Toshikazu Otani. 1st Freshers Conference, Tokyo, June 2017 Received the Excellent Presentation Award

  9. Changes in absorption of digoxin during 5-FU-induced gastrointestinal disorders. Keiichi Shimoto, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. 1st Freshers Conference, Tokyo, June 2017 Received the Excellent Presentation Award

  10. Usage of continuous infusion of lidocaine for cancer pain. Miwako Uemori, Ikuo Gomei, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. The 11th Annual Meeting of the Japanese Society of Palliative Medicine and Pharmacy, Sapporo, 2017.6

2016年

2016

Original paper

  1. In silico evaluation of warfarin-bucolome therapy. Ohtani H, Hakoda R, Imaoka A, Akiyoshi T. Biopharm Drug Dispos .37: 232-242 (2016)

Conference presentation

  1. Changes in the absorption dynamics of dabigatran during irinotecan-induced gastrointestinal disorders and its factors. Tomoki Hattori, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  2. Analysis of CYP2C9 inhibitory properties of grapefruit juice components and resveratrol.  Mari Uchiyama, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  3. Comparison of inhibitory properties of various azole antifungal drugs against CYP3A4 genetic variants. Go Kawamura, Ayuko Imaoka, Takeshi Akiyoshi, Hideyuki Hibino, Takuya Araki, Mitsue Miyazaki,  FP  Guengerich, Katsunori Nakamura, Tomonori Nakamura, Kojiro Yamamoto, Toshikazu Otani. The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  4. Comparative analysis of Gefitinib's inhibitory properties against various genetic polymorphisms of CYP2D6. Yurika Senba, Hideyuki Hibino, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani.  The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  5. Transactions of unapproved and unlicensed drugs at internet auctions. Moemi Fujii, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  6. Effect of metal cations on Caco-2 monolayer membrane permeability of levofloxacin prodrug. Kayo Wakabayashi, Ayuko Imaoka, Takeshi Akiyoshi, Kenji Matsuyama, Toshikazu Otani. 137th Annual Meeting of the Japanese Society of Pharmaceutical Sciences, Sendai, 2017.3

  7. The interaction between phenobarbital and activated carbon is attenuated by diet. Ayuko Imaoka, Yuka Kogata, Takeshi Akiyoshi, Toshikazu Otani. The 137th Annual Meeting of the Pharmaceutical Society of Japan, Sendai, 2017.3

  8. Examination of factors involved in in-hospital death of patients with neuromuscular disease who tried enteral nutrition. Shingo Konno, Yuko Okuyama, Mayumi Murata, Takeshi Akiyoshi, Emi Ishima, Takeshi Matsumon, Hideki Kobayashi, Shinya Kusachi, Toshikazu Otani, Toshiki Fujioka. 32nd Annual Meeting of the Japanese Society for Parenteral and Enteral Nutrition, Okayama, 2017.2

  9. Effect of 5-FU exposure on the absorption process of transporter substrate drugs. Keiichi Shimoto, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani.  The 10th Symposium on Young Medical and Pharmaceutical Sciences for the Next Generation, Maebashi, 2016.11

  10. Effect of gastrointestinal disorders caused by irinotecan on absorption of dabigatran. Tomoki Hattori, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. 26th Annual Meeting of the Japanese Society of Pharmaceutical Health Care, Kyoto, September 2016

  11. Fluctuations in the expression of various drug transporters during 5-FU-induced gastrointestinal disorders. Keiichi Shimoto, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani.  11th Transporter Study Group, Kyoto, 2016.7

2015年

2015

Original paper

  1. Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.  Akiyoshi T, Ishiuchi M, Imaoka A, Ohtani H.  Drug Metabol Pharmacokinet. 30 (4): 321-324 (2015)

  2. Dose-dependent estimation of systemic side effects at subnormal doses.  Rieko Mitsui, Takeshi Akiyoshi, Ayuko Imaoka, Mayumi Mochizuki, Toshikazu Otani.  Pharmaceutical informatics. 17 (2): 77-86 (2015)

  3. Illegal drug transactions at internet auctions and the actual situation of monitoring and deletion by the organizer. Toshikazu Otani, Ayuko Imaoka, Takeshi Akiyoshi.  Pharmacy magazine.  135 (3): 529-534 (2015)

Invited lecture at the conference

  1. Current status and future progress of pharmaceutical care and sciences in Japan.  Hisakazu Ohtani.  25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care International Symposium, Yokohama (November 2015)

Conference presentation

  1. Student exchange program between Keio University and US universities for international clinical practice.  Ohtani H, Foster P, Kanke M, Nakamura T, Abe Y, Mochizuki M. 2015 ACCP Global Conference on Clinical Pharmacy. San Francisco, CA, USA (2015.10)

  2. In vitro-in vivo comparison of interactions between ciprofloxacin and various metal cations.  Ayuko Imaoka, Kazumi Yamamiya, Takeshi Akiyoshi, Toshikazu Otani. The 136th Annual Meeting of the Pharmaceutical Society of Japan, Yokohama, 2016.3

  3. The expression level of P-gp is markedly increased during gastrointestinal disorders caused by 5-FU.  Keiichi Shimoto, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. The 136th Annual Meeting of the Pharmaceutical Society of Japan, Yokohama, 2016.3

  4. Elucidation of factors affecting the strength of grapefruit-drug interactions.  Yuri Kamei, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. The 136th Annual Meeting of the Pharmaceutical Society of Japan, Yokohama, 2016.3

  5. CYP3A4 A systematic comparison of the inhibitory strength of MBI inhibitors to the metabolic activity of each mutant molecular species.  Rina Naito, Takeshi Akiyoshi, Ayuko Imaoka, Hideyuki Hibino, Takuya Araki, Mitsue Miyazaki, FP Guengerich, Katsunori Nakamura, Tomonori Nakamura, Kojiro Yamamoto, Toshikazu Otani. The 136th Annual Meeting of the Pharmaceutical Society of Japan, Yokohama, 2016.3

  6. Effect of diet on drug interaction between amlodipine and activated charcoal in the gastrointestinal tract.  Kohei Seki, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care, Yokohama, 2015.11

  7. Effects of anticancer drug-induced gastrointestinal disorders on the dabigatran-clarithromycin drug interaction.  Naoki Wada, Takeshi Akiyoshi, Ayuko Imaoka, Kazushige Tsujii, Toshikazu Otani. 9th Symposium on Young Medical and Pharmaceutical Sciences for the Next Generation, Chiba, 2015.11

  8. A systematic comparison of the inhibitory properties of competitive inhibitors against the CYP3A4 genetic variant.  Kanako Aya, Takeshi Akiyoshi, Ayuko Imaoka, Hideyuki Hibino, Takuya Araki, Mitsue Miyazaki, FP Guengerich, Katsunori Nakamura, Tomonori Nakamura, Kojiro Yamamoto, Toshikazu Otani.  Received the Excellent Presentation Award

~2014年

2014

Original paper

  1. Decrease in ciprofloxacin absorption by polyvalent metal cations is not fully controlled to chelation or adsorption.  Imaoka A, Hattori M, Akiyoshi T, Ohtani H.  Drug Metabol Pharmacokinet. 29 (5): 414-418 (2014)

  2. Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice.  KogureN, Akiyoshi T, Imaoka A, Ohtani H.  Biopharm Drug Dispos.  35: 373-381 (2014)

Invited lecture at the conference

  1. Understanding pharmacokinetics from drug information . Toshikazu Otani. Osaka Pharmaceutical University 66th Public Education Course, Osaka (2014.5)

  2. Basic Pharmacy Course Practical reading of drug information. Toshikazu Otani. Nagano Prefectural Women's Pharmacist Association Workshop, Nagano (2014.7)

  3. Pharmacokinetics to be read from the package insert. Toshikazu Otani. Tokyo Minato-ku Pharmacist Association 2014 Second District Workshop, Tokyo (February 2015)

Conference presentation

  1. Relative comparison of the effects of aluminum on small intestinal epithelial cell monolayer membrane permeation of new quinolone antibacterial agents. Eri Taniuchi, Ayuko Imaoka, Takeshi Akiyoshi, Toshikazu Otani. Medical Pharmacy Forum 2014 / 22nd Clinical Pharmacy Symposium Tokyo, Abstracts p244 (2014.6)

  2. Does Mechanism-based inhibition of CYP3A4 occur in a substrate-dependent manner? Yuko Ishikawa, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. Medical Pharmacy Forum 2014 / 22nd Clinical Pharmacy Symposium Tokyo, Abstracts p244 (2014.6)

  3. The actual situation of illegal drug listings in online auctions and monitoring and deletion by the organizers. Toshikazu Otani, Ayuko Imaoka, Takeshi Akiyoshi.

  4. Examination of the ideal way of ward drug business in a ward specializing in cancer patients. Hideyuki Hibino, Yoshinori Makino, Haruo Iwase, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani, Kenichi Hayashi. p428 (2014/9)

  5. MBI properties of verapamil and its metabolites for various CYP3A4 mutants. Takeshi Akiyoshi, Takuto Ohashi, Ayuko Imaoka, Hideyuki Hibino, Takuya Araki, Mitsue Miyazaki, FP Guengerich, Katsunori Nakamura, Tomonori Nakamura, Kojiro Yamamoto, Tomonori Otani. . 135th Annual Meeting of the Japanese Society of Pharmaceutical Sciences Kobe (March 2015)

  6. Comparison of inhibitory properties of various competitive inhibitors against CYP3A4 genetic variants. Kanako Aya, Yuki Kobayashi, Takeshi Akiyoshi, Ayuko Imaoka, Hideyuki Hibino, Takuya Araki, Mitsue Miyazaki, FP Guengerich, Katsunori Nakamura, Tomonori Nakamura, Yasujiro Yamamoto Toshikazu. The 135th Annual Meeting of the Japanese Pharmacy Society Kobe (March 2015)

  7. Predicting the strength of interaction between various new quinolone antibacterial agents and aluminum from the Caco-2 cell line. Ayuko Imaoka, Eri Taniuchi, Takeshi Akiyoshi, Toshikazu Otani. The 135th Annual Meeting of the Japanese Society of Pharmaceutical Sciences Kobe (March 2015)

  8. Effect of anticancer drug-induced gastrointestinal disorders on the pharmacokinetics and efficacy of dabigatran. Kazunari Tsujii, Takeshi Akiyoshi, Ayuko Imaoka, Toshikazu Otani. The 135th Annual Meeting of the Pharmaceutical Society of Japan Kobe (March 2015)

医学部 病院薬剤学教室の業績はこちら

bottom of page